Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens

Journal of the National Cancer Institute

Volumn 101, Issue 14, 2009, Pages 1028-1029

  Thomssen, Christoph ^a   Harbeck, Nadia ^b   Dittmer, Juergen ^a   Abraha Spaeth, Shanti R ^c   Papendick, Nancy ^a   Paradiso, Angelo ^d   Lisboa, Bjoern ^c   Jaenicke, Fritz ^c   Schmitt, Manfred ^e   Vetter, Martina ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE EXTRACT; UROKINASE;

ADJUVANT CHEMOTHERAPY; BREAST; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; CORE NEEDLE BIOPSY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; HIGH RISK PATIENT; HUMAN; LABORATORY DIAGNOSIS; LETTER; MEDICAL SOCIETY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; TISSUE SECTION; ULTRASOUND;

BIOPSY, NEEDLE; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 67650834986     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp145     Document Type: Letter

References (7)

1. Harris L , Fritsche H , Mennel R , et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 ; 25 ( 33 ): 5287 -5312.
2. Harbeck N , Thomssen C , Berger U , et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat. 1999 ; 54 (2) : 147 -157.
3. Annecke K , Schmitt M , Euler U , et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem. 2008 ; 45 : 31 -45.
4. Jänicke F , Prechtl A , Thomssen C , et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identifi ed by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001 ; 93 (12) : 913 -920.
5. Look MP , van Putten WLK , Duffy MJ , et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002 ; 94 (2) : 116 -128.
6. Goldhirsch A , Glick JH , Gelber RD , et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005 ; 16 (10) : 1569 -1583.
7. Schmitt M , Sturmheit AS , Welk A , et al. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. Methods Mol Med. 2006 ; 120 : 245 -265.